Daiichi Sankyo Company, Limited (TYO:4568)
Japan · Delayed Price · Currency is JPY 2,794.00
-60.50 (-2.12%)
Sep 4, 2026, 3:30 PM JST
Daiichi Sankyo Company Employees
Daiichi Sankyo Company had 20,171 employees as of March 31, 2026. The number of employees increased by 406 or 2.05% compared to the previous year.
Employees
20,171
Change (1Y)
406
Growth (1Y)
2.05%
Revenue / Employee
110.22M JPY
Profits / Employee
13.03M JPY
Market Cap
5.09T
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 20,171 | 406 | 2.05% |
| Mar 31, 2025 | 19,765 | 1,039 | 5.55% |
| Mar 31, 2024 | 18,726 | 1,291 | 7.40% |
| Mar 31, 2023 | 17,435 | 977 | 5.94% |
| Mar 31, 2022 | 16,458 | 425 | 2.65% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Takeda Pharmaceutical Company | 47,029 |
| Otsuka Holdings | 37,758 |
| HOYA Corporation | 37,752 |
| Olympus | 28,138 |
| M3, Inc. | 17,010 |
| Astellas Pharma | 14,099 |
| Eisai | 10,543 |
| Shionogi & | 6,223 |
Daiichi Sankyo Company News
- 7 days ago - New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk - Business Wire
- 9 days ago - TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer - Business Wire
- 11 days ago - Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization - Business Wire
- 11 days ago - Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio - Business Wire
- 18 days ago - Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial - Business Wire
- 25 days ago - Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China - PRNewsWire
- 5 weeks ago - Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results - Business Wire
- 5 weeks ago - Daiichi Sankyo Company Earnings Call Transcript: Q1 2027 - Transcripts